|
KMID : 0545120220320010001
|
|
Journal of Microbiology and Biotechnology
2022 Volume.32 No. 1 p.1 ~ p.5
|
|
|
COVID-19 Drug Development
|
|
Kim Seung-Taek
|
|
|
Abstract
|
|
|
|
Diagnostics, vaccines, and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease 2019 (COVID-19). Diagnostic tools based on RT-PCR were developed early in the COVID-19 pandemic and were urgently required for quarantine (testing, tracing and isolation). Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19. Drug development has been conducted in various ways including drug repurposing, convalescent plasma therapy, and monoclonal antibody development. Among the above efforts, this review examines COVID-19 drug development along with the related and upcoming challenges.
|
|
|
KEYWORD
|
|
|
COVID-19, SARS-CoV-2, drug repurposing, monoclonal antibody, convalescent plasma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|